JP2016510769A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016510769A5 JP2016510769A5 JP2015561850A JP2015561850A JP2016510769A5 JP 2016510769 A5 JP2016510769 A5 JP 2016510769A5 JP 2015561850 A JP2015561850 A JP 2015561850A JP 2015561850 A JP2015561850 A JP 2015561850A JP 2016510769 A5 JP2016510769 A5 JP 2016510769A5
- Authority
- JP
- Japan
- Prior art keywords
- fibrosis
- composition
- compound
- salt
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 24
- 150000001875 compounds Chemical class 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 13
- 201000010099 disease Diseases 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 230000003176 fibrotic effect Effects 0.000 claims 10
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 10
- 206010016654 Fibrosis Diseases 0.000 claims 6
- 230000004761 fibrosis Effects 0.000 claims 6
- 208000019425 cirrhosis of liver Diseases 0.000 claims 4
- 230000009787 cardiac fibrosis Effects 0.000 claims 3
- 230000002500 effect on skin Effects 0.000 claims 3
- 231100000241 scar Toxicity 0.000 claims 3
- 102000008186 Collagen Human genes 0.000 claims 2
- 108010035532 Collagen Proteins 0.000 claims 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- 208000025865 Ulcer Diseases 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 229920001436 collagen Polymers 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000000428 dust Substances 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 206010035653 pneumoconiosis Diseases 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 238000011200 topical administration Methods 0.000 claims 2
- 231100000397 ulcer Toxicity 0.000 claims 2
- 230000029663 wound healing Effects 0.000 claims 2
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 1
- 208000033116 Asbestos intoxication Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000032544 Cicatrix Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 206010011985 Decubitus ulcer Diseases 0.000 claims 1
- 206010048768 Dermatosis Diseases 0.000 claims 1
- 208000008960 Diabetic foot Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 1
- 208000032984 Intraoperative Complications Diseases 0.000 claims 1
- 206010023330 Keloid scar Diseases 0.000 claims 1
- 208000005230 Leg Ulcer Diseases 0.000 claims 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- 208000002720 Malnutrition Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 208000004210 Pressure Ulcer Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 201000010001 Silicosis Diseases 0.000 claims 1
- 206010040943 Skin Ulcer Diseases 0.000 claims 1
- 206010050207 Skin fibrosis Diseases 0.000 claims 1
- 206010040925 Skin striae Diseases 0.000 claims 1
- 206010040954 Skin wrinkling Diseases 0.000 claims 1
- 208000031439 Striae Distensae Diseases 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 claims 1
- 230000003042 antagnostic effect Effects 0.000 claims 1
- 208000010123 anthracosis Diseases 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 206010003441 asbestosis Diseases 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 230000002595 cold damage Effects 0.000 claims 1
- 150000001879 copper Chemical class 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 230000008021 deposition Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000002532 enzyme inhibitor Substances 0.000 claims 1
- 229940125532 enzyme inhibitor Drugs 0.000 claims 1
- 239000007789 gas Substances 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 208000010710 hepatitis C virus infection Diseases 0.000 claims 1
- 208000029570 hepatitis D virus infection Diseases 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 230000001969 hypertrophic effect Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 229940124589 immunosuppressive drug Drugs 0.000 claims 1
- 239000012678 infectious agent Substances 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 229940125798 integrin inhibitor Drugs 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 229910052744 lithium Inorganic materials 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- 230000001071 malnutrition Effects 0.000 claims 1
- 235000000824 malnutrition Nutrition 0.000 claims 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229960004378 nintedanib Drugs 0.000 claims 1
- XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 claims 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 1
- 208000015380 nutritional deficiency disease Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 claims 1
- 229960003073 pirfenidone Drugs 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 229940075993 receptor modulator Drugs 0.000 claims 1
- 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 230000037387 scars Effects 0.000 claims 1
- 201000004409 schistosomiasis Diseases 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 239000000779 smoke Substances 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 230000008833 sun damage Effects 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 230000037303 wrinkles Effects 0.000 claims 1
- 239000011701 zinc Substances 0.000 claims 1
- 229910052725 zinc Inorganic materials 0.000 claims 1
- VJWTXJHQIHSUJV-UHFFFAOYSA-O CCCCCc1cc(O)c(Cc2ccccc2)c(CC(OO[NH+]=O)=O)c1 Chemical compound CCCCCc1cc(O)c(Cc2ccccc2)c(CC(OO[NH+]=O)=O)c1 VJWTXJHQIHSUJV-UHFFFAOYSA-O 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361798427P | 2013-03-15 | 2013-03-15 | |
| US61/798,427 | 2013-03-15 | ||
| PCT/CA2014/000237 WO2014138907A1 (en) | 2013-03-15 | 2014-03-14 | Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016510769A JP2016510769A (ja) | 2016-04-11 |
| JP2016510769A5 true JP2016510769A5 (https=) | 2017-04-13 |
| JP6381557B2 JP6381557B2 (ja) | 2018-08-29 |
Family
ID=51535670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015561850A Expired - Fee Related JP6381557B2 (ja) | 2013-03-15 | 2014-03-14 | 肺線維症、肝線維症、皮膚線維症、及び心線維症の治療のための置換芳香族化合物 |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US9884802B2 (https=) |
| EP (1) | EP2970088B1 (https=) |
| JP (1) | JP6381557B2 (https=) |
| KR (1) | KR102303493B1 (https=) |
| CN (1) | CN105143170B (https=) |
| AR (1) | AR095427A1 (https=) |
| AU (1) | AU2014231649C1 (https=) |
| BR (1) | BR112015023129A2 (https=) |
| CA (1) | CA2905633C (https=) |
| CL (1) | CL2015002725A1 (https=) |
| DK (1) | DK2970088T3 (https=) |
| EA (1) | EA031511B1 (https=) |
| ES (1) | ES2780825T3 (https=) |
| IL (1) | IL241164B (https=) |
| MX (1) | MX375261B (https=) |
| MY (1) | MY194727A (https=) |
| NZ (1) | NZ712745A (https=) |
| PH (1) | PH12015502012A1 (https=) |
| PL (1) | PL2970088T3 (https=) |
| PT (1) | PT2970088T (https=) |
| SG (1) | SG11201507274PA (https=) |
| TW (2) | TWI742541B (https=) |
| UY (1) | UY35401A (https=) |
| WO (1) | WO2014138907A1 (https=) |
| ZA (1) | ZA201507062B (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2649156T3 (es) | 2013-01-14 | 2018-01-10 | Incyte Holdings Corporation | Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim |
| PE20191245A1 (es) | 2013-01-15 | 2019-09-18 | Incyte Holdings Corp | Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim |
| TWI742541B (zh) * | 2013-03-15 | 2021-10-11 | 英商邊緣生物科技有限公司 | 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物 |
| EA201690458A1 (ru) | 2013-08-23 | 2016-07-29 | Инсайт Корпорейшн | Фуро- и тиенопиридинкарбоксамиды, используемые в качестве ингибиторов pim-киназы |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
| BR112017007426A2 (pt) * | 2014-10-10 | 2018-01-16 | Prometic Pharma Smt Limited | compostos aromáticos substituídos e composições farmacêuticas para prevenir e tratar osteoporose |
| KR20170072352A (ko) * | 2014-11-12 | 2017-06-26 | 프로메틱 파마 에스엠티 리미티드 | 조직 자가-회복 및 재생을 위한 치환된 방향족 화합물 및 약제학적 조성물 |
| MA41120A (fr) * | 2014-12-02 | 2017-10-10 | Afimmune Ltd | Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci |
| MA47141A (fr) | 2015-05-13 | 2019-11-06 | Ds Biopharma Ltd | Compositions comprenant du15-oxo-epa ou du 15-oxo-dgla et leurs procédés de préparation et d'utilisation |
| WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
| US10046007B2 (en) * | 2015-06-24 | 2018-08-14 | Prescient Pharma, Llc | Compositions and methods for treatment of short telomere disorders |
| TWI734699B (zh) | 2015-09-09 | 2021-08-01 | 美商英塞特公司 | Ｐｉｍ激酶抑制劑之鹽 |
| US9920032B2 (en) | 2015-10-02 | 2018-03-20 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| IL243707A0 (en) | 2016-01-20 | 2016-05-01 | Galmed Res And Dev Ltd | Treatment to regulate the microbiota in the intestine |
| US11197870B2 (en) | 2016-11-10 | 2021-12-14 | Galmed Research And Development Ltd | Treatment for hepatic fibrosis |
| RU2020119415A (ru) * | 2017-11-15 | 2021-12-16 | Галапагос Нв | Соединения и их фармацевтические композиции для применения при лечении фиброзных заболеваний |
| WO2019113487A1 (en) | 2017-12-08 | 2019-06-13 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
| US20210205253A1 (en) * | 2018-05-31 | 2021-07-08 | The Asan Foundation | Use Of Stearic Acid For Preventing Or Treating Pulmonary Fibrosis |
| US11820834B2 (en) | 2018-07-10 | 2023-11-21 | Novmetapharma Co., Ltd. | Polymorphic forms of Cyclo (-His-Pro) and methods of use to treat kidney disease |
| SG11202103011YA (en) | 2018-10-11 | 2021-04-29 | Basf As | Aromatic compounds and pharmaceutical uses thereof |
| EP3890717A4 (en) * | 2018-12-05 | 2022-08-24 | Liminal Biosciences Limited | USE OF SODIUM 2-(3-PENTYLPHENYL)ACETATE IN THE TREATMENT OF ALSTRÖM SYNDROME |
| EP3908668A4 (en) | 2019-01-11 | 2022-11-09 | University of Virginia Patent Foundation | COMPOSITIONS AND METHODS FOR PREDICTING THE DECREASE IN LUNG FUNCTION IN IDIOPATHIC LUNG FIBROSIS |
| WO2020181163A1 (en) * | 2019-03-06 | 2020-09-10 | Tobira Therapeutics, Inc. | Lipid-based formulation of cenicriviroc |
| KR102133151B1 (ko) | 2019-03-28 | 2020-07-13 | 주식회사 노브메타파마 | Chp(사이클로-히스프로)를 포함하는 복막 섬유증의 예방, 개선 또는 치료용 조성물 |
| WO2021015218A1 (ja) * | 2019-07-24 | 2021-01-28 | 国立大学法人九州大学 | 転写関連因子を標的とする線維化疾患の予防または治療 |
| CN112441916A (zh) * | 2019-08-29 | 2021-03-05 | 广东药科大学 | 新型苯乙酸衍生物、其制备方法及其作为药物的用途 |
| US20240043372A1 (en) * | 2020-10-06 | 2024-02-08 | Pharmaceutique Ingenew Inc. | Substituted aromatic compounds and pharmaceutical compositions thereof |
| US12053467B2 (en) * | 2020-12-18 | 2024-08-06 | NovMeta Pharma Co., Ltd. | Method of treating fibrosis |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20012434A1 (it) | 2001-11-20 | 2003-05-20 | Dompe Spa | Acidi 2-aril-propionici e composizioni farmaceutiche che li contengono |
| CA2761061A1 (en) * | 2009-05-04 | 2010-11-11 | Prometic Biosciences Inc. | Salts of 3-pentylphenylacetic acid and pharmaceutical uses thereof |
| EA022445B1 (ru) * | 2009-05-04 | 2016-01-29 | Прометик Байосайенсиз Инк. | Замещенные ароматические соединения, композиции на их основе и их фармацевтические применения |
| CN105997967B (zh) | 2010-10-27 | 2019-08-23 | 普罗米蒂克医药Smt有限公司 | 用于治疗癌症的化合物和组合物 |
| CN102070433B (zh) * | 2010-12-27 | 2013-03-27 | 桂林师范高等专科学校 | 芳香基乙酸类衍生物的制备方法 |
| TWI742541B (zh) * | 2013-03-15 | 2021-10-11 | 英商邊緣生物科技有限公司 | 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物 |
| TWI689490B (zh) * | 2013-03-15 | 2020-04-01 | 英商邊緣生物科技有限公司 | 用於治療纖維化之經取代之芳族化合物及相關方法 |
| KR20170072352A (ko) * | 2014-11-12 | 2017-06-26 | 프로메틱 파마 에스엠티 리미티드 | 조직 자가-회복 및 재생을 위한 치환된 방향족 화합물 및 약제학적 조성물 |
-
2014
- 2014-03-12 TW TW109106077A patent/TWI742541B/zh not_active IP Right Cessation
- 2014-03-12 TW TW103108714A patent/TWI689489B/zh not_active IP Right Cessation
- 2014-03-13 UY UY0001035401A patent/UY35401A/es not_active Application Discontinuation
- 2014-03-13 AR ARP140100971A patent/AR095427A1/es unknown
- 2014-03-14 US US14/775,882 patent/US9884802B2/en not_active Expired - Fee Related
- 2014-03-14 MX MX2015012886A patent/MX375261B/es active IP Right Grant
- 2014-03-14 PT PT147626071T patent/PT2970088T/pt unknown
- 2014-03-14 KR KR1020157029285A patent/KR102303493B1/ko not_active Expired - Fee Related
- 2014-03-14 NZ NZ712745A patent/NZ712745A/en not_active IP Right Cessation
- 2014-03-14 CN CN201480015002.6A patent/CN105143170B/zh not_active Expired - Fee Related
- 2014-03-14 CA CA2905633A patent/CA2905633C/en active Active
- 2014-03-14 ES ES14762607T patent/ES2780825T3/es active Active
- 2014-03-14 AU AU2014231649A patent/AU2014231649C1/en not_active Ceased
- 2014-03-14 MY MYPI2015002292A patent/MY194727A/en unknown
- 2014-03-14 WO PCT/CA2014/000237 patent/WO2014138907A1/en not_active Ceased
- 2014-03-14 EA EA201591774A patent/EA031511B1/ru not_active IP Right Cessation
- 2014-03-14 SG SG11201507274PA patent/SG11201507274PA/en unknown
- 2014-03-14 JP JP2015561850A patent/JP6381557B2/ja not_active Expired - Fee Related
- 2014-03-14 DK DK14762607.1T patent/DK2970088T3/da active
- 2014-03-14 BR BR112015023129A patent/BR112015023129A2/pt not_active Application Discontinuation
- 2014-03-14 PL PL14762607T patent/PL2970088T3/pl unknown
- 2014-03-14 EP EP14762607.1A patent/EP2970088B1/en active Active
-
2015
- 2015-09-03 IL IL241164A patent/IL241164B/en active IP Right Grant
- 2015-09-09 PH PH12015502012A patent/PH12015502012A1/en unknown
- 2015-09-15 CL CL2015002725A patent/CL2015002725A1/es unknown
- 2015-09-22 ZA ZA2015/07062A patent/ZA201507062B/en unknown
-
2017
- 2017-12-22 US US15/852,977 patent/US10450258B2/en not_active Expired - Fee Related
-
2019
- 2019-09-24 US US16/580,747 patent/US11267779B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016510769A5 (https=) | ||
| JP2016512202A5 (https=) | ||
| TWI689490B (zh) | 用於治療纖維化之經取代之芳族化合物及相關方法 | |
| RU2010144637A (ru) | Замещенные гамма-лактамы в качестве терапевтических агентов | |
| EA201001669A1 (ru) | Замещенные пиримидин-5-карбоксамиды 281 | |
| JP2011527332A5 (https=) | ||
| WO2014174524A8 (en) | A novel composition for nonalcoholic fatty liver disease (nafld) | |
| EA201101671A1 (ru) | Замещенные производные аминопропионовой кислоты в качестве ингибиторов неприлизина | |
| EA200601350A1 (ru) | Азотсодержащие гетероциклические производные и их фармацевтические применения | |
| WO2012116176A3 (en) | Asymmetric ureas and medical uses thereof | |
| RU2012118974A (ru) | Комбинации ингибитора pi3k и ингибитора мек | |
| SG10201806714PA (en) | C7-fluoro substituted tetracycline compounds | |
| WO2008109991A8 (en) | Inhibitors of carnitine palmitoyltransferase and treating cancer | |
| EA201071039A1 (ru) | Новые производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40 | |
| JP2017523219A5 (https=) | ||
| RU2013147739A (ru) | Фармацевтическая композиция | |
| IN2012DN02502A (https=) | ||
| RU2011108486A (ru) | ПРИМЕНЕНИЕ ПРОИЗВОДНЫХ ПЕПТИДА Wnt5-a ДЛЯ ЛЕЧЕНИЯ МЕЛАНОМЫ И РАКА ЖЕЛУДКА | |
| JP2010505865A5 (https=) | ||
| RU2018142988A (ru) | Производные пиридиндикарбоксамида в качестве ингибиторов бромодомена | |
| GEAP202516802A (en) | Protac chimeric compound, preparation method thereof and use thereof | |
| MX2024014315A (es) | Compuestos amido heteroaromaticos utiles en el tratamiento de enfermedades hepaticas | |
| PE20212197A1 (es) | Formas de sal y cristalinas de un compuesto organico y composiciones farmaceuticas del mismo | |
| MX347325B (es) | Bloqueadores del canal de calcio de fenilalquilamina de accion corta y sus usos. | |
| EA200601286A1 (ru) | Фармацевтические композиции, содержащие ингибитор протонового насоса и прокинетический агент |